PARP1 Polyclonal Antibody

Mouse Testis lysates probed with PARP1 Polyclonal Antibody, Unconjugated (bs-20763R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.

Lane 1: Human K562 cell lysates; Lane 2: Human SH-SY5Y cell lysates; Lane 3: Human U251 cell lysates; Lane 4: Human Hela cell lysates probed with PARP1 Polyclonal Antibody, Unconjugated (bs-20763R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

$Paraformaldehyde-fixed, paraffin embedded Rat brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with PARP1 Polyclonal Antibody, Unconjugated (bs-20763R) at 1:200 overnight at 4\u00b0C, DAB staining.$

Paraformaldehyde-fixed, paraffin embedded Rat brain; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with PARP1 Polyclonal Antibody, Unconjugated (bs-20763R) at 1:200 overnight at 4\u00b0C, DAB staining.

$293T cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20\u2103 for 20 min at room temperature, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with PARP1 Polyclonal Antibody(bs-20763R)at 1:100 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).$

293T cells were fixed with 4% PFA for 10min at room temperature,permeabilized with 90% ice-cold methanol for 20 min at -20\u2103 for 20 min at room temperature, and incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with PARP1 Polyclonal Antibody(bs-20763R)at 1:100 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2%BSA in PBS, followed by secondary antibody incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).

Applications

WB
ELISA
FCM
IHC-P

Reactivity

Human
Mouse
Rat

Predicted Reactivity

Cow
Sheep
Pig
Rabbit

Overview
Catalog #	bs-20763R
Product Name	PARP1 Polyclonal Antibody
Applications	WB, ELISA, FCM, IHC-P
Reactivity	Human, Mouse, Rat
Predicted Reactivity	Cow, Sheep, Pig, Rabbit
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human PARP1
Immunogen Range	581-650/1014
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	6352
Swiss Prot	P09874
Subcellular location	Nucleus
Synonyms	RANTES; CCL5; TCP228; Small Inducible Cytokine A5; CCL5; SISd; MGC17164; SCYA5; RANTES; D17S136E; SIS-delta; chemokine (C-C motif) ligand 5; regulated on activation normal T cell expressed and secreted; chemokine (C-C motif) ligand 5; T-cell-specific protein RANTES; C-C motif chemokine 5; EoCP; Eosinophil chemotactic cytokine; RANTES(3-68); RANTES(4-68); CCL5_HUMAN;
Background	Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. Binds to CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils.
Application Dilution
WB	1:300-5000
ELISA	1:500-1000
FCM	1:20-100
IHC-P	1:200-400